The Lead Episode 156: A Discussion of The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial
Availability
On-Demand
Cost
$0.00
Credit Offered
No Credit Offered

In this episode of The Lead, host Christopher Kowalewski, MD, is joined by John M. Mandrola, MD, and Nassir F. Marrouche, MD, FHRS, to discuss the journal article, The Association Between Atrial Fibrillation Burden and Quality of Life: A Substudy of the SHAM-PVI Trial. Together, they explore the relationship between atrial fibrillation burden and quality of life, reviewing findings from this substudy of the SHAM-PVI Trial and discussing their relevance to patient-centered outcomes.

  • Review the key findings from the SHAM-PVI Trial substudy examining the association between atrial fibrillation burden and quality of life.
  • Discuss the relationship between atrial fibrillation burden and patient-reported quality-of-life outcomes.
  • Explore the implications of assessing both arrhythmia burden and quality of life when evaluating treatment outcomes in atrial fibrillation.

Podcast Contributors

Host: Christopher Kowalewski, MD 

Guests: 

John M. Mandrola, MD
Nassir F. Marrouche, MD, FHRS

All relevant financial relationships have been mitigated.

Host and Contributor Disclosure(s):

Christopher Kowalewski, MD  

No relevant disclosures

 

John M. Mandrola, MD 

No relevant disclosures

 

Nassir F. Marrouche, MD, FHRS 

  • Honoraria/Speaking/Consulting Fee/Speaker’s Bureau: Biosense Webster, Inc., Boston Scientific, AtriCure, Inc., Abbott, Sanofi
  • Research: Abbott, Biosense Webster, Inc., Medtronic, Siemens, General Electric, Boston Scientific, Sanofi, Samsung


Staff Disclosu
re(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):

S. Sailor: No relevant financial relationships with ineligible companies to disclose.
E. Downward: No relevant financial relationships with ineligible companies to disclose.